Dogwood Completes Enrollment in Phase 2b Trial for CINP Treatment
Event summary
- Dogwood Therapeutics completed enrollment of 239 patients in its Phase 2b trial for Halneuron®, treating chemotherapy-induced neuropathic pain (CINP).
- Topline data from the trial is expected in November 2026.
- The trial is being conducted at approximately 25 sites in the U.S.
- Halneuron® is a non-opioid, NaV 1.7 analgesic with FDA fast track designation for CINP.
The big picture
Dogwood's completion of enrollment in the Halneuron® Phase 2b trial marks a critical step in addressing a significant unmet need in CINP treatment, a condition with no FDA-approved therapies. The trial's success could position Halneuron® as a first-in-class non-opioid analgesic, aligning with broader industry shifts toward non-addictive pain management solutions. The company's strategic focus on neuropathic disorders and its backing by CK Life Sciences Int’l. underscore its ambition to become a key player in this niche.
What we're watching
- Clinical Efficacy
- Whether Halneuron® demonstrates significant pain improvement compared to placebo in the upcoming topline data.
- Regulatory Pathway
- The potential for accelerated approval given the FDA's fast track designation for CINP.
- Pipeline Progress
- The timeline and outcomes of the forthcoming SP16 IV Phase 1b trial funded by the National Cancer Institute.
Related topics